Cell Therapy Next Current Issue

The following articles appeared in the print edition of Cell Therapy Next.

Table of Contents

• A decade of success: CAR-T pioneers reflect on past, look toward future Drew Amorosi
• CAR T-cell therapy shows vaccine effect in child with advanced sarcoma Drew Amorosi
• FDA grants orphan drug designation to CAR T-cell therapy for advanced gastric cancers
• FDA grants orphan drug designation to natural killer cell therapy for multiple myeloma
• FDA grants priority review to idecabtagene vicleucel for advanced multiple myeloma
• FDA grants priority review to melflufen for refractory multiple myeloma
• FDA grants rare pediatric disease designation to cell therapy for sickle cell disease
• FDA seeks more data about cell therapy for pediatric GVHD
• Autologous vs. allogeneic CAR-T: Decisions must be made ‘carefully and deliberately’ Drew Amorosi
• CAR-T-associated cardiac toxicity ‘limited and reversible’ in younger patients with ALL Drew Amorosi
• Lisocabtagene maraleucel could be ‘CAR T-cell treatment of choice’ for lymphoma subset Drew Amorosi
• Neurotoxicity after CAR T-cell therapy has no effect on survival in lymphoma subset Drew Amorosi
• CAR-T plus pembrolizumab shows ‘superior’ safety, promising responses in advanced lymphoma Drew Amorosi
• CAR-T viewed as ‘pinnacle’ of immunotherapy for advanced ALL Drew Amorosi
• COVID-19, manufacturing challenges limit cell and gene therapy progress, FDA official says Drew Amorosi
• City of Hope reaches deal to commercialize scorpion toxin-based CAR T-cell therapy Drew Amorosi
• MD Anderson, Allogene partner on development of allogeneic CAR T-cell therapies Drew Amorosi